New clinical trial shows that algae-based omega-3 lecithin AlmegaPL® provides better cardiovascular health support compared to traditional omega-3 fish oils
HOUSTON, Feb. 15, 2024 /PRNewswire/ -- Qualitas Health, LLC (dba iwi life) The results of a new clinical trial show evidence that the microalgae-derived AlmegaPL®, the foundational ingredient produced by iwi life™, delivers clinically relevant results decreasing triglycerides by 14% and remnant cholesterol such as very-low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL) by up to 25%.1,2 "This marks the second clinical trial endorsing the use of AlmegaPL® algal lecithin to support cardiovascular health in a generally healthy population," says Dr. Eneko Ganuza, a principal investigator who led the research.
- The new clinical trial led by Dr. Ganuza and sponsored by Qualitas Health was initiated to uncover just how effective an over-the-counter supplement can be in supporting cardiovascular health in the real-world population.
- The findings support existing beliefs that EPA-only omega-3s like AlmegaPL® could provide greater cardiovascular benefits when compared to traditional sources of omega-3s like fish and krill oil that contain both EPA and DHA.
- This highlights the use of naturally sourced AlmegaPL® algal oil as an over-the-counter supplement to help support cardiovascular health in the general healthy population."
- There is something about the unique polar form in which this algal lecithin yields the omega-3s that prove highly beneficial to our heart health."